Upadacitinib Reduces Extraintestinal Manifestations of UC: Study

Researchers evaluated phase 3 data comparing the oral JAK inhibitor with placebo for treating anemia, peripheral arthropathy, axial arthropathy, and other extraintestinal manifestations.
Medscape Medical News

source https://www.medscape.com/viewarticle/969264?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost